Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

FHTX 11.12.2024

Full Press ReleaseSEC FilingsOur FHTX Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
  • 12.16.2024 - Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
  • 12.04.2024 - Citi Global Healthcare Conference

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
  • 12.30.2024 - 4 Statement of changes in beneficial ownership of securities

CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jefferies London Healthcare Conference, the 7thAnnual Evercore HealthCONx Conference, and the Citi Global Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Jefferies London Healthcare Conference

  • Fireside Chat: Tuesday, November 19, 2024, at 11:30 a.m. GMT in London, UK
  • Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
  • Please find a link to the webcasthere
  • Management will also participate in one-on-one meetings on Tuesday, November 19

7thAnnual Evercore HealthCONx Conference

  • Fireside Chat: Tuesday, December 3, 2024, at 1:20 p.m. EST in Coral Gables, Florida
  • Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
  • Please find a link to the webcasthere
  • Management will also participate in one-on-one meetings on Tuesday, December 3

Citi Global Healthcare Conference

  • Management will participate in one-on-one meetings on Wednesday, December 4 in Miami, Florida

A webcast of both fireside chats can be accessed under “Events & Presentations” in the Investors section of the Company’s website,www.foghorntx.com, and will be available for 30 days.

About Foghorn Therapeutics

Foghorn®Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control®platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website atwww.foghorntx.comfor more information on the Company, and follow us onX(formerly Twitter) andLinkedIn.

Contact:

Karin Hellsvik, Foghorn Therapeutics Inc.khellsvik@foghorntx.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com